Upfront dexrazoxane for the reduction of anthracycline-induced cardiotoxicity in adults with preexisting cardiomyopathy and cancer: a consecutive case series

Table 2 Outcomes of Eight Patients with Preexisting Cardiomyopathy Undergoing Anthracycline Chemotherapy for Any Cancer, With or Without The Cardioprotectant, Dexrazoxane

Patient #. Sex; age, years	Elevated biomarker concentrations^a		Clinical HF	New arrhythmia	Clinical outcome	Chemotherapy cycles received, n	Cancer outcomes
Patient #. Sex; age, years	Troponin	BNP	Clinical HF	New arrhythmia	Clinical outcome	Chemotherapy cycles received, n	Cancer outcomes
Without dexrazoxane
1. M; 87	Not available	Not available	Yes	NSVT	Cardiogenic shock, HF, death	6	Died
2. M; 66	Not available	Not available	Yes	No	Cardiogenic shock, HF, death	3	Died
3. M; 65	Not available	Not available	Yes	No	Required ICD	2	Alive at 12 months after Allo SCT
With dexrazoxane
4. F; 67	No	No	No	NSVT	Alive at 30 months	6	Complete remission
5. F; 75	No	No	No	No	Alive at 18 months, Needed BiV ICD implantation	6	Complete remission
6. F 70	No	No	No	No	Alive at 12 months	6	Partial response
7. M; 73	No	No	No	No	Alive at 15 months	6	Complete remission
8. F; 68	No	No	No	NSVT	Alive at 12 months	6	Complete response

NSVT Non-sustained ventricular tachycardia, HF heart failure, ICD implantable cardiodefibrillator, Allo SCT allogeneic stem cell transplantation, BiV ICD bi-ventricular implantable cardiodefibrillator
^aThreshold values for elevation were > 0.03 ng/mL for cTnI and > 250 pg/mL for BNP

ISSN: 2057-3804